| Autor: |
Nogueira, Miguel, Lau, Catarina, Teixeira, Maria dos Anjos, Peixeiro, Rita, Cabral, Renata, Fernandes, Iolanda |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2024, Vol. 38 Issue 1, pe86-e88, 3p |
| Abstrakt: |
This article discusses the use of alemtuzumab as a treatment for Sézary syndrome, a rare type of primary cutaneous T-cell lymphoma. The study reports on the experiences of 28 patients who were treated with alemtuzumab as either a first-line or second-line drug. The results showed that 71.4% of patients responded to the first treatment cycle, with 15 achieving a complete response and 5 having a partial response. The median time of survival for the group was 92 months. The study also found that the expression of CD52 in abnormal T cells may be related to treatment response. Overall, alemtuzumab demonstrated effective antitumoral activity and a favorable safety profile. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text